Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

780.12 +14.69 (+1.92%)
Streaming Delayed Price Updated: 10:09 AM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
argenx announces Annual General Meeting of Shareholders on May 6, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at TD Cowen 46th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Highlights 2026 Strategic Priorities
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Leadership Transition Marking Next Evolution of Growth
From argenx SE
Via GlobeNewswire
News headline image
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Results of Extraordinary General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
From argenx SE
Via GlobeNewswire
News headline image
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
From argenx SE
Via GlobeNewswire
News headline image
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
From argenx SE
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
From argenx SE
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.